NOVELOS THERAPEUTICS
Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The Company's compound, NOV-002 is a small-molecule compound based on a formulation of oxidized glutathione that has been administered to approximately 1,000 cancer patients in clinical trials. As of December 31, 2009, NOV-002 was in Phase II development for solid tumors in combination with chemotherapy. The Company's second glutathione-based compound, NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties.
NOVELOS THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1996-01-01
Address:
Madison, Wisconsin, United States
Country:
United States
Website Url:
http://www.novelos.com
Total Employee:
11+
Status:
Closed
Contact:
6179646331
Total Funding:
85.8 M USD
Technology used in webpage:
SPF Google Analytics Nginx PHP CentOS Apache 2.2 DOSarrest Uniregistry
Current Advisors List
Paul L Berns Member of the Board of Directors @ Novelos Therapeutics Board_member 2013-11-01
Current Employees Featured
Jamey Weichert
Jamey Weichert Chief Scientific Officer @ Novelos Therapeutics Chief Scientific Officer
James Caruso
James Caruso President, Chief Executive Officer & Director @ Novelos Therapeutics President, Chief Executive Officer & Director 2015-06-01
Founder
Jamey Weichert
Stock Details
Company's stock symbol is OTCBB:NVLT
Investors List
Advantage Capital
Advantage Capital investment in Convertible Note - Novelos Therapeutics